Cancer patients, physicians, and nurses differ in their attitudes toward the decisional role in do-not-resuscitate decision-making.

Autor: Saltbæk L; Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib Juuls Vej 7, DK-2730, Herlev, Denmark. lesa@cancer.dk.; Survivorship and Inequality in Cancer, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100, Copenhagen, Denmark. lesa@cancer.dk.; Department of Oncology, Zealand University Hospital, Ringstedgade 61, DK-4700, Næstved, Denmark. lesa@cancer.dk., Michelsen HM; Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib Juuls Vej 7, DK-2730, Herlev, Denmark., Nelausen KM; Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib Juuls Vej 7, DK-2730, Herlev, Denmark., Theile S; Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib Juuls Vej 7, DK-2730, Herlev, Denmark., Dehlendorff C; Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100, Copenhagen, Denmark., Dalton SO; Survivorship and Inequality in Cancer, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100, Copenhagen, Denmark.; Department of Oncology, Zealand University Hospital, Ringstedgade 61, DK-4700, Næstved, Denmark., Nielsen DL; Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib Juuls Vej 7, DK-2730, Herlev, Denmark.

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Dec; Vol. 28 (12), pp. 6057-6066. Date of Electronic Publication: 2020 Apr 15.

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.

Autor: Buhl ASK; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark. anna-buhl@hotmail.com.; Medical Prognosis Institute, Hoersholm, Denmark. anna-buhl@hotmail.com., Christensen TD; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark., Christensen IJ; Department of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Nelausen KM; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark., Balslev E; Department of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark., Knoop AS; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Brix EH; Department of Oncology, Nordsjaellands Hospital, Copenhagen University Hospital, Hilleroed, Denmark., Svensson E; Department of Oncology, Zealand University Hospital, Roskilde, Naestved, Denmark., Glavicic V; Department of Oncology, Zealand University Hospital, Roskilde, Naestved, Denmark., Luczak A; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark., Langkjer ST; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Linnet S; Department of Oncology, Regional Hospital West Jutland, Herning, Denmark., Jakobsen EH; Department of Oncology, Vejle Sygehus, Vejle, Denmark., Bogovic J; Department of Oncology, Hospital of Southern Jutland, Soenderborg, Denmark., Ejlertsen B; The Danish Breast Cancer Cooperative Group, DBCG Secretariat, Rigshospitalet, Copenhagen, Denmark., Rasmussen A; Medical Prognosis Institute, Hoersholm, Denmark., Hansen A; Medical Prognosis Institute, Hoersholm, Denmark., Knudsen S; Medical Prognosis Institute, Hoersholm, Denmark., Nielsen D; Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark., Jensen PB; Medical Prognosis Institute, Hoersholm, Denmark.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2018 Nov; Vol. 172 (2), pp. 391-400. Date of Electronic Publication: 2018 Aug 11.

Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer.

Autor: Kümler I; Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark, Iben.Kumler@regionh.dk., Parner VK, Tuxen MK, Skjoldbye B, Bergenfeldt M, Nelausen KM, Nielsen DL

Publikováno v: La Radiologia medica [Radiol Med] 2015 Jun; Vol. 120 (6), pp. 536-41. Date of Electronic Publication: 2015 Jan 09.

A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.

Autor: Knudsen, Steen¹ (AUTHOR) sknudsen@allarity.com, Hansen, Anker¹ (AUTHOR), Foegh, Marie² (AUTHOR), Petersen, Steen¹ (AUTHOR), Mekonnen, Hana³ (AUTHOR), Jia, Lin³ (AUTHOR), Shah, Preeti³ (AUTHOR), Martin, Victoria³ (AUTHOR), Frykman, Gregory⁴ (AUTHOR), Pili, Roberto⁵ (AUTHOR)

Publikováno v: PLoS ONE. 8/30/2023, Vol. 18 Issue 8, p1-16. 16p.

Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer.

Autor: Nielsen DL; Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. dornie01@heh.regionh.dk, Nørgaard H, Vestermark LW, Pfeiffer P, Jensen BK, Nelausen KM, Bergenfeldt M, Hermann KL, Jensen BV

Publikováno v: Breast (Edinburgh, Scotland) [Breast] 2012 Aug; Vol. 21 (4), pp. 556-61. Date of Electronic Publication: 2012 Jun 04.